Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The goal of this interventional study is to evaluate efficiency and safety in prior one-line
treated diffuse large B-cell lymphoma. The main questions it aims to answer are:
- Complete remission rate
- Objective remission rate
- Progression-free survival
- tolerance Participants will recevied a minimum of 2 and a maximum of 6 cycles of
R-GemOx(rituximab 375 mg/m2 IV on day 1 , Gemcitabine 1000 mg/m2, Oxaliplatin 100 mg/m2
IV on day 2) and 60 mg selinexor on days 1, 8, and 15 of each cycle